By integrating single copies of the entire synthetic transposon into multiple transcriptionally active genomic loci, ATUM’s Leap-In transposases will advance your cell line development workflow by:
Using our VectorGPS® design platform, we can design, synthesize and transfect multiple synthetic transposons in parallel, each harboring up to 4 independently-controlled, codon-optimized ORFs with altered expression ratios. Furthermore, we can identify the optimal construct with our stable pool productivity and product quality. This means the balance of expression for each subunit in a multi-subunit protein can be optimized for increased productivity and product quality. Using ATUM's VectorGPS®, you can decrease the risk of incomplete correlation between the best ratios of transiently transfected genes, and the optimal stable expression of each subunit.
Control of protein subunit expression ratios in 2-, 3- and 4-ORF Leap-In transposons.
ATUM currently uses three mammalian host cell lines with lineage traceability and documented provenance. All CHO cell lines are adapted to commercially-available chemically-defined serum-free formulations. No raw materials of animal origin are used during CHO cell line generation or our cell line development process.
ATUM's Leap-In transposase can increase the efficiency of your stable expression cell line construction. With most Leap-In transfected cells integrating multiple copies of the transposon into their genomes, ATUM's technology ensures:
Product quality (glycan relative abundance %, charge %) and productivity is comparable between stable pool and derivative clones.
The clonal distribution within the stable pools generated by ATUM's Leap-In technology, are strongly biased towards high productivity. This reduces the number of clones that need to be tested to no more than a few hundred. Using Solentim VIPS™ seeding and clonal identification instruments, ATUM efficiently isolates high producing clones.
Static 96 well plate
24 deep-well scale, 7 day fed batch clone ranking
Highest ranked clones, 125 ml shake, 14 day fed batch
Screening, characterizing and ranking fewer clones eliminates the need to invest in expensive, high-throughput instrumentation for cell line engineering and allows more cell line development projects to be managed simultaneously.